Active Ingredient: Azithromycin
Up to half of the cases are non-specific. The diagnosis of urethritis is confirmed by demonstrating an excess of polymorpho-nuclear leucocytes PMNLs in a stained smear.
Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children. Pediatr Infect Dis J. Ower respiratory illnesses promote FEV 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease.
Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. A comparison of moxifloxacin and azithro-mycin in the treatment of acute exacerbations of chronic bronchitis.
MLS resistance phenotypes and mechanisms in S. Abstract 3.
Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate release regimen.
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada. Double-blind randomized study comparing the efficacies and safeties of a short 3-day course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis.
Prospective observational study of patient-reported outcomes for azithromycin versus usual care in the treatment of bacterial acute exacerbation of chronic bronchitis.
In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
Antibiotics in chronic obstructive pulmonary disease: a meta-analysis.
J Am Med Assoc. Azithromycin versus pivampicillin in the treatment of acute exacerbations of chronic bronchitis: a single-blind, double-dummy, multicentre study. The evidence base for management of acute exacerbations of COPD: Clinical practice guideline, part 1.